Agenus, with FDA approval in sight, showcases anti-PD-1 data

[cafead]

via Agenus is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer.

article source